scholarly journals Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

2013 ◽  
Vol 74 (3) ◽  
pp. 538-546 ◽  
Author(s):  
Jonathan Kay ◽  
Roy Fleischmann ◽  
Edward Keystone ◽  
Elizabeth C Hsia ◽  
Benjamin Hsu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Controlled Trials ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Pooled Data

scholarly journals Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials

Drug Safety ◽  
2017 ◽  
Vol 41 (4) ◽  
pp. 429-440 ◽  
Author(s):  
Dao Thai-Cuarto ◽  
Christopher F. O’Brien ◽  
Roland Jimenez ◽  
Grace S. Liang ◽  
Joshua Burke
Keyword(s):  
Controlled Trials ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Pooled Data ◽  
Cardiovascular Profile

Biologics registries

2013 ◽  
pp. 257-263
Author(s):  
David Isenberg ◽  
Angela Zink
Keyword(s):  
Rheumatoid Arthritis ◽  
Life Experience ◽  
Real Life ◽  
Cancer Development ◽  
Controlled Trials ◽  
Side Effect Profile ◽  
Risk Of Infection ◽  
Biologic Drugs ◽  
Double Blind

Double-blind controlled trials undertaken over the past two decades have established the short-term effectiveness and side-effect profile of biologic drugs for patients with rheumatoid arthritis and related diseases. However, the development of biologics registers to capture ’real-life experience’ and explore long-term effectiveness and complications is equally important. In this chapter, we demonstrate how these registers have identified long-term joint benefits, a reduction in cardiovascular mortality, reassurance concerning fears about cancer development, and a balanced view of the risk of infection.

Sign in / Sign up

Export Citation Format

Share Document